Physician profile
Jerald Hurdle
NPI 1184648784
$16,682.75
in general payments reported to CMS, 2019-2025
25 companies · $5,010 in 2025
The $5,010 reported for 2025 was more than what 89% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $222 · 2021: $888 · 2022: $2,185 · 2023: $2,811 · 2024: $4,849 · 2025: $5,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $1,069 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,345.14 |
| Consulting Fee | $1,068.75 |
| Education | $255.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,110.16 | 2020-2025 | |
| Leo Pharma INC. | $1,982.40 | 2022-2025 | Adbry, Anzupgo |
| Amgen INC. | $1,498.79 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $1,284.98 | 2020-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,016.91 | 2019-2025 | |
| Janssen Biotech, INC. | $977.72 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $974.19 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $932.15 | 2024-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $632.34 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $615.30 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Novartis Pharmaceuticals Corporation | $508.78 | 2019-2025 | |
| Genzyme Corporation | $414.72 | 2019-2025 | |
| Allergan, INC. | $362.14 | 2019 | |
| Incyte Corporation | $249.75 | 2021-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $243.00 | 2019-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $176.16 | 2023-2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $156.18 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $140.60 | 2023-2025 | Blu-U, Odomzo, Ilumya |
| Dermavant Sciences, INC. | $115.19 | 2023-2024 | Vtama |
| Organon LLC | $110.10 | 2025 | |
| Sandoz INC. | $107.63 | 2023-2024 | Hyrimoz |
| Genentech USA, INC. | $23.98 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.87 | 2021 | |
| Celgene Corporation | $17.40 | 2019 | |
| Dusa Pharmaceuticals, INC. | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerald Hurdle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.